Literature DB >> 11030525

Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease.

H Yasui1, E C Gabazza, O Taguchi, J Risteli, L Risteli, H Wada, H Yuda, T Kobayashi, H Kobayashi, K Suzuki, Y Adachi.   

Abstract

Activation of the coagulation system in the alveolar space plays an important role in the pathogenesis of interstitial lung disease (ILD) and pulmonary fibrosis. The protein C (PC) pathway is the main modulator of coagulation activation. This study evaluated whether dysfunction of the PC pathway is associated with increased collagen synthesis in the intraalveolar space of patients with ILD. This study comprised 22 patients with ILD; of these, five had idiopathic pulmonary fibrosis (IPF), nine had sarcoidosis-associated ILD, and eight had collagen vascular disease-associated ILD (CVD-ILD). Thrombin-antithrombin complex (TAT) was measured as a marker of coagulation activation. As markers of the PC pathway activity, the concentration of activated PC-PC inhibitor (APC-PCI) complex and the APC-PCI/PC ratio were measured and, as a marker of collagen synthesis, the concentration of aminoterminal propeptide of type III procollagen (PIIINP) was measured in bronchoalveolar lavage fluid (BALF) of ILD patients. TAT was significantly increased in BALF from ILD patients as compared to control subjects. The concentrations of PIIINP were significantly elevated in patients with ILD as compared to healthy subjects. In contrast, the concentration of APC-PCI and the values of APC-PCI/PC ratio were significantly decreased in BALF from patients with ILD. BALF concentration of PIIINP was significantly and inversely correlated with the concentration of APC-PCI and with the APC-PCI/PC ratio. These findings suggest that dysfunction of the protein C pathway may have important physiopathologic implications in the development of pulmonary fibrosis in ILD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030525     DOI: 10.1177/107602960000600404

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  9 in total

1.  Serum analysis of coagulation factors in IPF and NSIP.

Authors:  E Bargagli; C Madioni; N Bianchi; R M Refini; R Cappelli; P Rottoli
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

2.  Drotrecogin alfa (activated) prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1beta in rats.

Authors:  S S Wong; N N Sun; J D Hyde; L Ruiz; E Meigs; B R Herrin; C D Fastje; S J Macdonald; M L Witten
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.

Authors:  D C Howell; N R Goldsack; R P Marshall; R J McAnulty; R Starke; G Purdy; G J Laurent; R C Chambers
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

4.  Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation.

Authors:  Ling Wang; Julie A Bastarache; Nancy Wickersham; Xiaohui Fang; Michael A Matthay; Lorraine B Ware
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-10       Impact factor: 6.914

5.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

Review 6.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

7.  Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Syeda Fatima Naqvi; Amir Humza Sohail; Dhairya A Lakhani; James Maurer; Sarah Sofka; Yousaf B Hadi
Journal:  Pulm Med       Date:  2021-11-25

8.  Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis.

Authors:  Stijn Willems; Willems Stijn; Stijn E Verleden; Bart M Vanaudenaerde; Marijke Wynants; Wynants Marijke; Christophe Dooms; Dooms Christophe; Jonas Yserbyt; Yserbyt Jonas; Jana Somers; Somers Jana; Eric K Verbeken; Geert M Verleden; Wim A Wuyts
Journal:  Ann Thorac Med       Date:  2013-01       Impact factor: 2.219

9.  HEPBURN - investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial.

Authors:  Gerie J Glas; Johannes Muller; Jan M Binnekade; Berry Cleffken; Kirsten Colpaert; Barry Dixon; Nicole P Juffermans; Paul Knape; Marcel M Levi; Bert G Loef; David P Mackie; Manu Malbrain; Marcus J Schultz; Koenraad F van der Sluijs
Journal:  Trials       Date:  2014-03-25       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.